Top

Published in:

Open Access 01-12-2021 | Human Papillomavirus | Research article

Analysis of PET parameters as prognosticators of survival and tumor extent in Oropharyngeal Cancer treated with surgery and postoperative radiotherapy

Authors: Kyu Hye Choi, Jin Ho Song, Eun Young Park, Ji Hyun Hong, Ie Ryung Yoo, Youn Soo Lee, Dong-Il Sun, Min-Sik Kim, Yeon-Sil Kim

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

Positron-emission tomography (PET) is widely used to detect malignancies, but consensus on its prognostic value in oropharyngeal cancer has not been established. The purpose of this study was to analyze the PET parameters associated with tumor extent and survival in resectable oropharyngeal cancer.

Methods

The PET parameters in oropharyngeal cancer patients with regional node metastasis who underwent surgery and postoperative radiotherapy between January 2005 and January 2019 were analyzed. We calculated the SUVmax, tumor-to-liver ratio (TLR), metabolic tumor volume (MTV, volume over SUV 2.5), and total lesion glycolysis (TLG, MTV x mean SUV) of the primary lesion and metastatic nodes. Histologic findings, patient survival, and recurrence were reviewed in the medical records.

Results

Fifty patients were included, and the PET parameters were extracted for 50 primary lesions and 104 nodal lesions. In the survival analysis, MTV and TLG of the primary lesions showed significant differences in overall survival (OS) and recurrence-free survival (RFS). In the multiple regression analysis, TLG of the primary lesion was associated with the depth of invasion (DOI). MTV of the nodes was a significant factor affecting extranodal extension (ENE).

Conclusions

PET parameters could be related with OS, RFS, DOI of the primary tumor, and ENE. PET would be expected to be a useful diagnostic tool as a prognosticator of survival and pathologic findings in oropharyngeal cancer.

Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32(4):623–48.PubMed

Bai B, Bading J, Conti PS. Tumor quantification in clinical positron emission tomography. Theranostics. 2013;3(10):787–801. https://doi.org/10.7150/thno.5629.CrossRefPubMedPubMedCentral

Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R. Tumor treatment response based on visual and quantitative changes in global tumor glycolysis using PET-FDG imaging. The visual response score and the change in Total lesion glycolysis. Clin Positron Imaging. 1999;2(3):159–71. https://doi.org/10.1016/S1095-0397(99)00016-3.CrossRefPubMed

Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, Rusch V. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol. 2004;22(16):3255–60. https://doi.org/10.1200/JCO.2004.11.109.CrossRefPubMed

Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110(8):1738–44. https://doi.org/10.1002/cncr.22974.CrossRefPubMed

Machtay M, Natwa M, Andrel J, Hyslop T, Anne PR, Lavarino J, Intenzo CM, Keane W. Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer. Head Neck. 2009;31(2):195–201. https://doi.org/10.1002/hed.20942.CrossRefPubMed

Higgins KA, Hoang JK, Roach MC, Chino J, Yoo DS, Turkington TG, Brizel DM. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value. Int J Radiat Oncol Biol Phys. 2012;82(2):548–53. https://doi.org/10.1016/j.ijrobp.2010.11.050.CrossRefPubMed

Moon SH, Hyun SH, Choi JY. Prognostic significance of volume-based PET parameters in cancer patients. Korean J Radiol. 2013;14(1):1–12. https://doi.org/10.3348/kjr.2013.14.1.1.CrossRefPubMed

Myers JN, Greenberg JS, Mo V, Roberts D. Extracapsular spread. A significant predictor of treatment failure in patients with squamous cell carcinoma of the tongue. Cancer. 2001;92(12):3030–6. https://doi.org/10.1002/1097-0142(20011215)92:12<3030::AID-CNCR10148>3.0.CO;2-P.CrossRefPubMed

10.

Ferlito A, Rinaldo A, Devaney KO, MacLennan K, Myers JN, Petruzzelli GJ, Shaha AR, Genden EM, Johnson JT, de Carvalho MB, Myers EN. Prognostic significance of microscopic and macroscopic extracapsular spread from metastatic tumor in the cervical lymph nodes. Oral Oncol. 2002;38(8):747–51. https://doi.org/10.1016/S1368-8375(02)00052-0.CrossRefPubMed

11.

Huang SH, O'Sullivan B. Overview of the 8th edition TNM classification for head and neck Cancer. Curr Treat Options in Oncol. 2017;18(7):40. https://doi.org/10.1007/s11864-017-0484-y.CrossRef

12.

Ravasz LA, Slootweg PJ, Hordijk GJ, Smit F, van der Tweel I. The status of the resection margin as a prognostic factor in the treatment of head and neck carcinoma. J Craniomaxillofac Surg. 1991;19(7):314–8. https://doi.org/10.1016/S1010-5182(05)80339-7.CrossRefPubMed

13.

Bradley PJ, MacLennan K, Brakenhoff RH, Leemans CR. Status of primary tumour surgical margins in squamous head and neck cancer: prognostic implications. Curr Opin Otolaryngol Head Neck Surg. 2007;15(2):74–81. https://doi.org/10.1097/MOO.0b013e328058670f.CrossRefPubMed

14.

O'Sullivan B, Huang SH, Su J, Garden AS, Sturgis EM, Dahlstrom K, Lee N, Riaz N, Pei X, Koyfman SA, Adelstein D, Burkey BB, Friborg J, Kristensen CA, Gothelf AB, Hoebers F, Kremer B, Speel EJ, Bowles DW, Raben D, Karam SD, Yu E, Xu W. Development and validation of a staging system for HPV-related oropharyngeal cancer by the international collaboration on Oropharyngeal cancer network for staging (ICON-S): a multicentre cohort study. Lancet Oncol. 2016;17(4):440–51. https://doi.org/10.1016/S1470-2045(15)00560-4.CrossRefPubMed

15.

Haughey BH, Sinha P, Kallogjeri D, Goldberg RL, Lewis JS Jr, Piccirillo JF, Jackson RS, Moore EJ, Brandwein-Gensler M, Magnuson SJ, Carroll WR, Jones TM, Wilkie MD, Lau A, Upile NS, Sheard J, Lancaster J, Tandon S, Robinson M, Husband D, Ganly I, Shah JP, Brizel DM, O’Sullivan B, Ridge JA, Lydiatt WM. Pathology-based staging for HPV-positive squamous carcinoma of the oropharynx. Oral Oncol. 2016;62:11–9. https://doi.org/10.1016/j.oraloncology.2016.09.004.CrossRefPubMedPubMedCentral

16.

Annunziata S, Cuccaro A, Calcagni ML, Hohaus S, Giordano A, Rufini V. Interim FDG-PET/CT in Hodgkin lymphoma: the prognostic role of the ratio between target lesion and liver SUVmax (rPET). Ann Nucl Med. 2016;30(8):588–92. https://doi.org/10.1007/s12149-016-1092-9.CrossRefPubMed

17.

Annunziata S, Cuccaro A, Tisi MC, Hohaus S, Rufini V. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV(max) (rPET). Ann Nucl Med. 2018;32(5):372–7. https://doi.org/10.1007/s12149-018-1243-2.CrossRefPubMed

18.

Porceddu SV, Pryor DI, Burmeister E, Burmeister BH, Poulsen MG, Foote MC, Panizza B, Coman S, McFarlane D, Coman W. Results of a prospective study of positron emission tomography-directed management of residual nodal abnormalities in node-positive head and neck cancer after definitive radiotherapy with or without systemic therapy. Head Neck. 2011;33(12):1675–82. https://doi.org/10.1002/hed.21655.CrossRefPubMed

19.

Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, Colevas AD, Iagaru AH, Graves EE, Loo BW Jr, et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;83(5):1514–20. https://doi.org/10.1016/j.ijrobp.2011.10.023.CrossRefPubMedPubMedCentral

20.

La TH, Filion EJ, Turnbull BB, Chu JN, Lee P, Nguyen K, Maxim P, Quon A, Graves EE, Loo BW Jr, et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2009;74(5):1335–41. https://doi.org/10.1016/j.ijrobp.2008.10.060.CrossRefPubMedPubMedCentral

21.

Choi KH, Yoo Ie R, Han EJ, Kim YS, Kim GW, Na SJ, Sun DI, Jung SL, Jung CK, Kim MS, et al. Prognostic value of metabolic tumor volume measured by (18)F-FDG PET/CT in locally advanced head and neck squamous cell carcinomas treated by surgery. Nucl Med Mol Imaging. 2011;45(1):43–51. https://doi.org/10.1007/s13139-010-0063-7.CrossRefPubMed

22.

Hsieh H-Y, Liu Y-C, Lin J-W, Lin J-C: Prognostic effects of the metabolic tumor volume and total lesion glycolysis in patients with advanced squamous cell carcinoma of head and neck. Ther Radiol Oncol. 2018;2(5):1–9. http://dx.doi.org/10.21037/tro.2018.01.08.

23.

Kim S, Oh S, Kim JS, Kim YK, Kim KH, Oh DH, Lee DH, Jeong WJ, Jung YH. Prognostic value of FDG PET/CT during radiotherapy in head and neck cancer patients. Radiat Oncol J. 2018;36(2):95–102. https://doi.org/10.3857/roj.2017.00577.CrossRefPubMedPubMedCentral

24.

Alluri KC, Tahari AK, Wahl RL, Koch W, Chung CH, Subramaniam RM. Prognostic value of FDG PET metabolic tumor volume in human papillomavirus-positive stage III and IV oropharyngeal squamous cell carcinoma. Am J Roentgenol. 2014;203(4):897–903. https://doi.org/10.2214/AJR.14.12497.CrossRef

25.

Park JO, Jung SL, Joo YH, Jung CK, Cho KJ, Kim MS. Diagnostic accuracy of magnetic resonance imaging (MRI) in the assessment of tumor invasion depth in oral/oropharyngeal cancer. Oral Oncol. 2011;47(5):381–6. https://doi.org/10.1016/j.oraloncology.2011.03.012.CrossRefPubMed

26.

Fujii T, Miyabe J, Yoshii T, Suzuki M, Otozai S, Komukai S, Kishikawa T, Takemoto N, Fukusumi T, Tatsumi M, Hatazawa J, Inohara H. Metabolic tumor volume of metastatic lymph nodes and survival after total laryngectomy in laryngeal and hypopharyngeal cancer. Oral Oncol. 2019;93:107–13. https://doi.org/10.1016/j.oraloncology.2019.04.011.CrossRefPubMed

27.

O'Sullivan B, Huang SH, Siu LL, Waldron J, Zhao H, Perez-Ordonez B, Weinreb I, Kim J, Ringash J, Bayley A, Dawson LA, Hope A, Cho J, Irish J, Gilbert R, Gullane P, Hui A, Liu FF, Chen E, Xu W. Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis. J Clin Oncol. 2013;31(5):543–50. https://doi.org/10.1200/JCO.2012.44.0164.CrossRefPubMed

28.

Quon H, Forastiere AA. Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: should we, how should we, and for whom? J Clin Oncol. 2013;31(5):520–2. https://doi.org/10.1200/JCO.2012.46.7746.CrossRefPubMed

29.

Masterson L, Moualed D, Masood A, Dwivedi RC, Benson R, Sterling JC, Rhodes KM, Sudhoff H, Jani P, Goon P: De-escalation treatment protocols for human papillomavirus-associated oropharyngeal squamous cell carcinoma. Cochrane Database Syst Rev. 2014;1(2):Cd010271. https://doi.org/10.1002/14651858.CD010271.pub2.

30.

Chotchutipan T, Rosen BS, Hawkins PG, Lee JY, Saripalli AL, Thakkar D, Eisbruch A, El Naqa I, Mierzwa ML. Volumetric (18) F-FDG-PET parameters as predictors of locoregional failure in low-risk HPV-related oropharyngeal cancer after definitive chemoradiation therapy. Head Neck. 2019;41(2):366–73. https://doi.org/10.1002/hed.25505.CrossRefPubMed

Title: Analysis of PET parameters as prognosticators of survival and tumor extent in Oropharyngeal Cancer treated with surgery and postoperative radiotherapy
Authors: Kyu Hye Choi
Jin Ho Song
Eun Young Park
Ji Hyun Hong
Ie Ryung Yoo
Youn Soo Lee
Dong-Il Sun
Min-Sik Kim
Yeon-Sil Kim
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Human Papillomavirus
Radiotherapy
Oropharyngeal Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08035-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Identification of significant genes as prognostic markers and potential tumor suppressors in lung adenocarcinoma via bioinformatical analysis

Comparison of clinicopathological features and long-term prognosis between mixed predominantly differentiated-type and pure differentiated-type early gastric cancer

KLF5-mediated Eppk1 expression promotes cell proliferation in cervical cancer via the p38 signaling pathway

Clinical significance of HRAS and KRAS genes expression in patients with non–small-cell lung cancer - preliminary findings

Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analyses

TGF-β protects osteosarcoma cells from chemotherapeutic cytotoxicity in a SDH/HIF1α dependent manner

Keynote webinar | Spotlight on antibody–drug conjugates in cancer